Trial Profile
A Phase 3, Multicenter, Open-Label Study of the Safety, Tolerability, Efficacy, and PK of ProMetic BioTherapeutics IGIV (Human) 10% in Adults and Children With Primary Immunodeficiency Diseases
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Immunoglobulin G (Primary)
- Indications Immunodeficiency disorders
- Focus Registrational; Therapeutic Use
- Sponsors Liminal BioSciences; ProMetic BioTherapeutics
- 11 Oct 2019 Status changed from active, no longer recruiting to completed.
- 18 Mar 2019 Planned End Date changed from 1 Feb 2019 to 1 Jul 2019.
- 18 Mar 2019 Planned primary completion date changed from 1 Feb 2019 to 1 Jul 2019.